Agenebio, Inc.

AgeneBio is a biopharmaceutical company developing therapeutics to treat neurological and psychiatric diseases, with a focus on preserving and restoring brain function in patients with neurodegeneration. The company's lead program, AGB101, is in late-stage clinical development for amnestic mild cognitive impairment due to Alzheimer's disease, and it is also evaluating GABA(A) α5 positive allosteric modulators for conditions including schizophrenia.